Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling

By Ju-Seog Lee, I. Chu, Jeonghoon Heo, D. Calvisi, Zong-tang Sun, T. Roskams, A. Durnez, A. Demetris, Snorri Thorgeirsson. Hepatology, 2004

875 citations recorded by the source corpus.

We analyzed global gene expression patterns of 91 human hepatocellular carcinomas (HCCs) to define the molecular characteristics of the tumors and to test the prognostic value of the expression profiles. Unsupervised classification methods revealed two distinctive subclasses of HCC that are highly associated with patient survival. This association was validated via 5 independent supervised learning methods. We also identified the genes most strongly associated with survival by using the Cox proportional hazards survival analysis. This approach identified a limited number of genes that accurately predicted the length of survival and provides new molecular insight into the pathogenesis of HCC. Tumors from the low survival subclass have strong cell proliferation and antiapoptosis gene expression signatures. In addition, the low survival subclass displayed higher expression of genes involved in ubiquitination and histone modification, suggesting an etiological involvement of these processes in accelerating the progression of HCC. In conclusion, the biological differences identified in the HCC subclasses should provide an attractive source for the development of therapeutic targets (e.g., HIF1a) for selective treatment of HCC patients. Supplementary material for this article can be found on the HEPATOLOGY Web site (http://interscience.wiley.com/jpages/0270‐9139/suppmat/index.html) (HEPATOLOGY 2004;40:667–676.)

Subfields: Cancer Research, Hepatology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/7886b8d87b64c9fdd990b6482ec84fc581b16131

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Hepatology

In Pathology and Forensic Medicine

Citations in the corpus

EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. (2008, methodology): “We carried out multidimensional scaling analysis based on the expression of EpCAM-coexpressed genes in both HCC cohort 1 and cohort 2 (Fig. 4B) stratified by EpCAM and AFP status, which resulted in four subgroups: A, B, C, and D. When a well-defined serum AFP cutoff ( 10 , 13, 29) was added to the s”
Identification of metastasis‐related microRNAs in hepatocellular carcinoma (2008, neutral): “021 Portal Vein Tumor Thrombi No 210 (87) 102 (78) 108 (98) Yes 29 (12) 29 (22) 0 <0.”
Deep Learning based multi-omics integration robustly predicts survival in liver cancer (2017, background): “To understand the HCC heterogeneity among patients, a considerable amount of work has been done to identify the HCC molecular subtypes (13-19).”
Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties (2009, methodology): “The determination of proliferation, apoptosis and ubiquitination index was described earlier (Lee et al., 2004b).”
Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer (2019, background): “Primary liver cancer, the second most lethal malignancy worldwide, is etiologically and biologically heterogeneous, comprising many molecularly unique subtypes (Boyault et al., 2007; Jusakul et al., 2017; Lee et al., 2004; TheCancerGenomeAtlasResearchNetwork, 2017; Ye et al., 2003).”
Focal Gains of Vascular Endothelial Growth Factor A and Molecular Classification of Hepatocellular Carcinoma (2008, methodology): “Combined annotations from marker gene lists, mutation analyses, and immunohistochemistry could associate three of five gene expression classes with previously described signaling pathway alterations (4, 5, 7).”
A Unique Metastasis Gene Signature Enables Prediction of Tumor Relapse in Early Stage Hepatocellular Carcinoma Patients (2010, positive): “The gene expression data of cohort 2 has been published earlier (20, 21).”
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets (2007, background): “Previous reports have also identified the two main transcriptomic group classification as a relevant survival predictor(22).”
Novel advancements in the management of hepatocellular carcinoma in 2008. (2008, background): “A gene signature able to discriminate two populations of good and poor survival was reported in HBV patients [42].”
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma (2017, positive): “Eight tumor-derived prognostic signatures were used to comparison: NCI proliferation (NCIP) signature (Lee et al., 2004), hepatic stem cells (HS) signatures (Lee et al.”
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells (2006, methodology): “Three distinct subgroups of HCC Having identified two subtypes of HCC that may reflect the origin of tumor cells, we next sought to assess the relationship of the newly identified subtypes with two previously recognized subclasses of HCC (clusters A and B) that were classified by applying unsuper”
Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. (2006, result): “The presence of a prognostic signature in primary HCC specimens was confirmed by several studies (Iizuka et al., 2003; Lee et al., 2004).”